CONTRAFECT Corp
CFRXDelisted Dec 27, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001478069
CONTRAFECT Corp was delisted on Dec 27, 2023; its insiders filed their last Form 4 on Feb 16, 2023; 40 institutions reported holding it in 13F filings for Q4 2022, worth $1.08M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:16 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2023 | Mar 24, 2022 | Mar 30, 2021 | Mar 18, 2020 | Mar 14, 2019 |
| Operating expenses | $64.6M | $47.3M | $34.2M | $27.9M | $31.1M |
| Research and development | $44.7M | $35.5M | $22.6M | $18.1M | $22.4M |
| Selling, general and administrative | $12.2M | $11.8M | $11.6M | $9.81M | $8.71M |
| Operating income | -$64.6M | -$47.3M | -$34.2M | -$27.9M | -$31.1M |
| Net income | -$65.2M | -$20.3M | -$28.2M | -$12.8M | -$37.7M |
| EPS, basic | $-124.97 | – | – | – | – |
| EPS, diluted | $-124.97 | – | – | – | – |
| Weighted shares, basic | 521.4K | – | – | – | – |
| Weighted shares, diluted | 521.4K | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2023 | Mar 24, 2022 | Mar 30, 2021 | Mar 18, 2020 | Mar 14, 2019 |
| Cash and equivalents | $8.91M | $16.7M | $15.5M | $24.2M | $8.32M |
| Short-term investments | $4.78M | $37.6M | $27.0M | – | $22.1M |
| Total current assets | $17.7M | $62.9M | $46.7M | $30.8M | $31.4M |
| Property, plant and equipment | $627.0K | $741.0K | $910.1K | $1.10M | $1.08M |
| Total assets | $20.7M | $66.8M | $51.1M | $35.0M | $32.9M |
| Accounts payable | $13.7M | $2.39M | $1.81M | $2.62M | $1.43M |
| Total current liabilities | $20.8M | $12.2M | $6.06M | $10.1M | $5.80M |
| Total liabilities | $32.5M | $17.4M | $38.5M | $19.5M | $27.3M |
| Shareholders' equity | -$11.9M | $49.4M | $12.6M | $15.5M | $5.54M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 31, 2023 | Mar 24, 2022 | Mar 30, 2021 | Mar 18, 2020 | Mar 14, 2019 |
| Operating cash flow | -$46.0M | -$41.1M | -$33.2M | -$27.4M | -$26.3M |
| Capital expenditures | $62.0K | – | – | $20.0K | $133.5K |
| Free cash flow | -$46.0M | – | – | -$27.4M | -$26.4M |
| Stock-based compensation | $3.87M | $3.19M | $2.58M | $1.45M | $1.56M |
| Investing cash flow | $32.1M | -$11.6M | -$27.4M | $22.0M | $17.2M |
| Financing cash flow | $6.14M | $53.9M | $51.9M | $21.3M | $10.4M |
| Net change in cash | -$7.75M | $1.17M | -$8.70M | $15.9M | $1.33M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 10, 2023 | 10.7M | −72.8% | SEC |
| Aug 10, 2023 | 10.7M | −72.8% | SEC |
| May 10, 2023 | 3.67M | −90.7% | SEC |
| Mar 24, 2023 | 1.57M | −96.0% | SEC |
| Nov 11, 2022 | 39.3M | 0.0% | SEC |
| Aug 12, 2022 | 39.3M | 0.0% | SEC |
| May 10, 2022 | 39.3M | 0.0% | SEC |
| Mar 17, 2022 | 39.3M | 0.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.